Abstract
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections.
Reference77 articles.
1. Mechanism of action of T-705 against influenza virus;Furuta;Antimicrob. Agents Chemother.,2005
2. Favipiravir (T-705), a novel viral RNA polymerase inhibitor;Furuta;Antivir. Res.,2013
3. Report on the Deliberation Results March 4, 2014 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare
https://www.pmda.go.jp/files/000210319.pdf
4. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase;Furuta;Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.,2017
5. The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase;Jin;PLoS ONE,2013
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献